Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Repligen Cp (RGEN)

Repligen Cp (RGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,834,754
  • Shares Outstanding, K 54,904
  • Annual Sales, $ 366,260 K
  • Annual Income, $ 59,930 K
  • 60-Month Beta 0.84
  • Price/Sales 29.93
  • Price/Cash Flow 82.63
  • Price/Book 7.04
Trade RGEN with:

Options Overview

Details
  • Implied Volatility 37.78%
  • Historical Volatility 36.87%
  • IV Percentile 5%
  • IV Rank 16.03%
  • IV High 58.06% on 10/30/20
  • IV Low 33.91% on 05/26/21
  • Put/Call Vol Ratio 0.35
  • Today's Volume 159
  • Volume Avg (30-Day) 176
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 6,948
  • Open Int (30-Day) 6,541

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.53
  • Number of Estimates 6
  • High Estimate 0.56
  • Low Estimate 0.49
  • Prior Year 0.42
  • Growth Rate Est. (year over year) +26.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
167.00 +18.17%
on 05/19/21
203.31 -2.94%
on 06/18/21
+25.35 (+14.74%)
since 05/18/21
3-Month
162.29 +21.60%
on 05/17/21
223.03 -11.52%
on 04/26/21
-2.67 (-1.33%)
since 03/18/21
52-Week
109.38 +80.42%
on 06/25/20
228.84 -13.76%
on 02/12/21
+83.31 (+73.06%)
since 06/18/20

Most Recent Stories

More News
Bristol-Myers (BMY) Partners Eisai for Antibody Drug Conjugate

Bristol-Myers (BMY) teams up with Eisai to co develop MORAb-202, an antibody drug conjugate (ADC).

BMY : 66.47 (-0.45%)
MRK : 76.61 (-0.80%)
RGEN : 197.34 (-1.15%)
BLUE : 33.15 (+0.52%)
Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate

Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.

BIIB : 388.44 (+1.28%)
RGEN : 197.34 (-1.15%)
BLPH : 4.09 (-5.54%)
BNTX : 212.42 (-0.83%)
Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies

Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.

GILD : 66.61 (-0.91%)
RGEN : 197.34 (-1.15%)
TECH : 431.90 (-2.99%)
KMDA : 5.74 (-0.69%)
Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM

The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.

RGEN : 197.34 (-1.15%)
TECH : 431.90 (-2.99%)
KMDA : 5.74 (-0.69%)
BPMC : 82.79 (-0.89%)
Regeneron (REGN) Announces Data on COVID-19 Antibody Cocktail

Regeneron (REGN) announces positive results from a phase III study on antibody cocktail, REGEN-COV.

REGN : 537.92 (+0.36%)
GSK : 39.84 (-1.80%)
RGEN : 197.34 (-1.15%)
VIR : 46.15 (+5.32%)
RAPT Reports Positive Data From Atopic Dermatitis Study

RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.

REGN : 537.92 (+0.36%)
SNY : 52.86 (-0.71%)
RGEN : 197.34 (-1.15%)
RAPT : 34.57 (+3.50%)
Axsome (AXSM) Plans NDA Filing for Fibromyalgia Drug in 2022

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-14, which is being developed as a treatment of fibromyalgia. The company will file an NDA in the fourth quarter of 2022.

RGEN : 197.34 (-1.15%)
ADPT : 39.45 (-0.93%)
AXSM : 67.35 (+1.22%)
BNTX : 212.42 (-0.83%)
Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers

Exelixis (EXEL) collaborates with Bristol Myers to evaluate its next-generation tyrosine kinase inhibitor in combination with immuno-oncology therapies in advanced solid tumors.

BMY : 66.47 (-0.45%)
EXEL : 22.41 (+1.27%)
NKTR : 17.00 (-1.39%)
RGEN : 197.34 (-1.15%)
Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa

Gilead (GILD) obtains FDA approval for the label expansion of HCV drug, Epclusa, to include children as well.

GSK : 39.84 (-1.80%)
NVO : 82.28 (-0.59%)
GILD : 66.61 (-0.91%)
RGEN : 197.34 (-1.15%)
Bristol Myers (BMY) Announces Data on CAR T Cell Therapy Breyanzi

Bristol Myers (BMY) announces positive data on CAR T cell therapy, Breyanzi, in the second-line setting for patients with relapsed or refractory large B-cell lymphoma.

BMY : 66.47 (-0.45%)
MRK : 76.61 (-0.80%)
RGEN : 197.34 (-1.15%)
BLUE : 33.15 (+0.52%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Business Summary

Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide....

See More

Key Turning Points

3rd Resistance Point 210.54
2nd Resistance Point 206.93
1st Resistance Point 202.13
Last Price 197.34
1st Support Level 193.72
2nd Support Level 190.11
3rd Support Level 185.31

See More

52-Week High 228.84
Last Price 197.34
Fibonacci 61.8% 183.20
Fibonacci 50% 169.11
Fibonacci 38.2% 155.01
52-Week Low 109.38

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar